(NYSE:CSL) LEIDEN, Netherlands--(BUSINESS WIRE)--VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational blood coagulation treatment VMX-C001.
(NYSE:CSL) SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Carlisle Companies Incorporated (NYSE:CSL) today announced participation in the following upcoming events with the financial community in the month of September: Morgan Stanley's 13th Annual Laguna Conference Wednesday, September 10, 2025 The Ritz-Carlton, Laguna Niguel 1 Ritz Carlton Dr, Dana Point, CA 92629 Zelman’s 2025 Annual Housing Summit Friday, September 12, 2025 InterContinental Boston 510 Atlantic Avenue, Boston, MA 02210 The Company’s investor pres
(NYSE:CSL) SCOTTSDALE, Ariz.--(BUSINESS WIRE)--The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) today approved a new share repurchase program authorizing management to buy back up to an additional 7.5 million shares of the Company’s common stock over an indefinite period of time or until terminated by the Board. These shares will be purchased at management’s direction from time to time in the open market at prevailing market prices, in privately negotiated transactions, or through bloc
MONTRÉAL, Aug. 20, 2025 /PRNewswire/ -- The CSL Group ("CSL") has deployed its newest addition to the fleet, MV CSL Flexvik, to support marine construction and aggregate logistics across Europe. This 18,003 DWT hybrid self-loading/unloading vessel has been engineered to deliver maximum...
Major strategic initiatives, including demerger, to transform CSL MELBOURNE, Aug. 19, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis....
Major strategic initiatives, including demerger, to transform CSL MELBOURNE, Aug. 18, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis....
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Carlisle Companies Incorporated (NYSE:CSL) today announced that it has priced a public offering of $500 million in aggregate principal amount of its 5.250% notes due September 15, 2035, and $500 million in aggregate principal amount of its 5.550% notes due September 15, 2040 (collectively, the “Notes”). Carlisle expects the offering to close on August 20, 2025, subject to customary closing conditions. Carlisle intends to use the net proceeds from the offering
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Carlisle Companies Incorporated (NYSE:CSL) today published its 2024 Corporate Sustainability Report, highlighting progress toward Carlisle's sustainability goals through its legacy of innovation in sustainability and culture of continuous improvement fostered through the Carlisle Operating System. “In 2024, we entered the next phase of our sustainability roadmap: generating shareholder value through sustainability,” said Chris Koch, Chair, President and Chief
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Carlisle Companies Incorporated (NYSE:CSL) today announced that its Board of Directors approved a 10% increase in the Company’s regular quarterly dividend from $1.00 to $1.10 per share, or to $4.40 per share on an annualized basis. The dividend is payable on September 2, 2025, to shareholders of record at the close of business on August 19, 2025. Chris Koch, Chair, President and Chief Executive Officer, said, “This year’s increase marks Carlisle’s 49th consec
ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a least squares mean of 89.2 percent, compared to placebo ANDEMBRY approval expands CSL's...
